| Objective:Ovarian cancer, in which epithelial carcinoma accouts forabout85-90%, is one of the three common female genital malignancy.Because of the difficulty of early diagnosis, its mortality is in the firstplace of gynecological cancer. Study of new marker expression andclinical significance in epithelial ovarian cancer is of great value for thediagnosis and prognosis of epithelial ovarian cancer. Protein SHP-2isinvolved in a variety of signal transduction processes, which is closelyrelated to many important cellular activities such as regulation of cellproliferation, differentiation, movement and apoptosis, also to theoccurrence and the development of a variety of malignant diseases. Inthis study, we apply immunohistochemical staining to research theexpression of protein SHP-2in epithelial ovarian cancer, and itsrelationship with pathological features and prognosis in epithelial ovariancancer.Methods:1We selected45cases of epithelial ovarian cancer patients’ paraffin andmedical information as study group, all of whom were inpatient in the fourthaffiliated hospital of Hebei medical university from January2008to December2009. Among all the patients selected, their ages ranged from40to70yearsold, with a median age of52years. In the study group, there are15cases ofovarian serous carcinoma,15cases of mucinous carcinoma, and15cases ofendometrial carcinoma patients;5cases of high-differentiated carcinoma,10cases of middle-differentiated carcinoma, and30cases of low-differentiated;according to FIGO stage, there are5cases of stageⅠ,9cases of stage Ⅱ,24cases of stage Ⅲ and7cases of stage Ⅳ, of which stageⅠ/Ⅱbelongs toearly stage(totally14cases), stage Ⅲ/Ⅳ belongs to late stage(totally31 cases);10cases with lymph node metastasis,35cases with no lymph nodemetastasis;22cases recurred in1year after operation,36cases recurred in3years, and there are9cases without recurrence. We selected paraffin andmedical information of normal ovarian tissue in the same period as the controlgroup.2Chip the selected paraffin blocks specimens consecutively to4μmthickness, apply immunohistochemistry to detect the expression of proteinSHP-2in epithelial ovarian cancer and normal ovarian, analyze therelationship between its expression and clinical pathological features andprognosis of epithelial ovarian cancer.3All data was analyzed by SPSS13.0software wrap,①count data usingchi-square test,②level data analysis using the rank sum test. α=0.05is atest level in the results of each group, and P＜0.05is considered statisticallysignificant.Results:1The expression and distribution of protein SHP-2Protein SHP-2mainly expressed in the cytoplasm, positive cytoplasmicstaining pale yellow to dark brown. The positive of SHP-2expression inepithelial ovarian cancer is77.78%, while in the normal ovarian tissue is0.00%. Compared this two group, the difference was statistically significant(P＜0.05).2relationship between the expression of protein SHP-2and clinicalpathological features of epithelial ovarian cancer2.1Protein SHP-2presented high expression in different pathological types ofepithelial ovarian cancer, and in serous, mucinous, endometrioid carcinoma,the expression positive rate is80.00%,73.33%and80.00%, compared witheach other, there were no significant differences(P＞0.05).2.2In high-differentiation, middle-differentiation, low-differentiation groups,SHP-2expression positive rates were40.00%,60.00%and90.00%, there wassignificant difference between the three(P＜0.05). In the high-differentiationgroup, strong positive expression rate of SHP-2was0.00%, in the middle-differentiation group was10.00%, and the low-differentiationgroup was40.00%, compared middle-differentiation group withhigh-differentiation group and low-differentiation group separately, thereshowed no significant difference(P＞0.05), while high-differentiationgroup compared with low-differentiation group, the difference was statisticallysignificant (P <0.05).2.3In the early (FIGOⅠ-Ⅱ) and late(FIGO Ⅲ-Ⅳ) stage of epithelialovarian cancer, the positive rate of SHP-2expression were57.10%and87.10%, having statistical difference (P<0.05); the strong positiveexpression rate of SHP-2in early stage group was7.14%, in late stage, it was64.52%, and there was significant difference between them (P <0.05).2.4The positive rate of SHP-2protein in lymph node metastasis andnon-metastasis of lymph node tissue of patients were90%and71.40%, comparison between them, there was no significant difference(P＞0.05); the strong positive expression rate of SHP-2in metastasis group was70.00%, while in the lymph node negative group, it was40.00%, there wasstatistically significant difference comparing the two(P <0.05).2.5There were21cases in the SHP-2positive group reccured within1year,and the recurrence rate was60.00%,32cases reccred within3years, and therecurrence rate was91.43%; in the SHP-2negative group,1case recurred in1year, and4cases recurred in3years, the recurrence rate of1year and3yearswere10.00%and40.00%. Compared1year recurrence rate of SHP-2positveand negative patients, the positive group was higher than that of the negativeone, there was statistically significant difference of the two (P<0.05);3years recurrence rate between positive and negative expression of SHP-2protein, SHP-2protein positive group was higher than that of the negativegroup, the difference was statistically significant (P <0.05).Conclusions:1Protein SHP-2expressed in a high level in epithelial ovarian cancer,while it didn’t express in normal ovarian tissues, so SHP-2can be used as anew marker of epithelial ovarian cancer diagnosis. 2The expression of protein SHP-2in epithelial ovarian cancer is closelyrelated to the clinical stages, and it has a certain relationship between thedegree of differentiation and lymph nodes metastasis, suggesting that proteinSHP-2may be involved in the proliferation, differentiation and migration oftumor cells, which may be used as therapeutic target in the treatment ofepithelial ovarian cancer.3The recurrence of epithelial ovarian cancer with high expression ofSHP-2was significantly increased, it can be used as a helpful indicator toevaluate the prognosis of epithelial ovarian cancer. |
PDF Full Text Request